Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

Business Wire 7-Dec-2017 5:02 PM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 P.M. ET in New York.

A live webcast of the presentation can be accessed on the investor page of Sage's website at A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeuticsis a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please

Image for Press Release 546745

View source version on

Investor Contact: Sage Therapeutics Paul Cox, 617-299-8377paul.cox@sagerx.comorMedia Contact:Suda Communications LLCMaureen L. Suda,

Source: Sage Therapeutics

Wait, Before You Leave...

Receive Anticipated Price Moves into Earnings

Enter your email address below to receive FREE daily information about expected earnings moves and upcoming earnings.
Market Chameleon